When It Announced A Deal With Australian Inflammatory Disease Specialist Mesoblast Back In November Last Year, Basel-Based Novartis Described Its Lead Candidate, Remestemcel-L, As
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
